News

LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, the founder of Restore Worldwide, ...
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...
QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, largely driven by sales ...
Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the PFS curves compared to the control arm at a ...
Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, ...
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. recently ...
Assuming that the Over-allotment is not exercised, the gross proceeds to J-Star from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by ...
CG Oncology thanks both Judge Rennie and the jury for their thoughtful evaluation and decisions in the case which represent a major victory for bladder cancer patients who could benefit from ...
LifeMD ® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including ...
Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 11:00 a.m. PST / 2:00 p.m. EST A live and archived webcast of the presentation will be available in the ...
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be ...
Beta Bionics expects to have full results from the PK-PD bridging trial in the second half of 2025, which will inform the go-forward development strategy for the glucagon candidate. Estimated total ...